IP Library Granted Patent US 10,786,817
Granted Patent B2
US 10,786,817 · App. 15/965,128 · Granted Sep 29, 2020

Devices and method for enrichment and alteration of cells and other particles

Inventors: Lotien Richard Huang (Chestnut Hill, MA); Thomas A. Barber (Sudbury, MA); Bruce L. Carvalho (Watertown, MA); Ravi Kapur (Sharon, MA); Paul Vernucci (Billerica, MA); Mehmet Toner (Charlestown, MA); Zihua Wang (Newton, MA)
Assignees: The General Hospital Corporation; GPB Scientific, LLC
B03C1/30B01L3/502746B01L3/502753B01L3/502761B03C1/32C12M47/04C12M47/06G01N1/4077G01N33/5044B01L2200/0647B01L2300/0816B01L2300/0864B01L2400/043B01L2400/0406B01L2400/0409B01L2400/0415B01L2400/0472B01L2400/0487B01L2400/086B03C2201/18B33Y80/00G01N1/40G01N2035/00237Y10T137/0318Y10T137/8593Y10T436/25Y10T436/25375
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,786,817
App. No.
15/965,128
Granted
Sep 29, 2020
Kind
B2
Abstract

The invention features devices and methods for the deterministic separation of particles. Exemplary methods include the enrichment of a sample in a desired particle or the alteration of a desired particle in the device. The devices and methods are advantageously employed to enrich for rare cells, e.g., fetal cells, present in a sample, e.g., maternal blood and rare cell components, e.g., fetal cell nuclei. The invention further provides a method for preferentially lysing cells of interest in a sample, e.g., to extract clinical information from a cellular component, e.g., a nucleus, of the cells of interest. In general, the method employs differential lysis between the cells of interest and other cells (e.g., other nucleated cells) in the sample.

Claims (29)

1. A method of enriching a sample in fetal cells relative to maternal cells, the method comprising:

(a) introducing a maternal blood sample into a microfluidic device capable of enriching fetal nucleated cells relative to maternal cells based on size, shape, deformability, or affinity to produce an enriched sample;

(b) lysing all cells in the enriched sample to release nuclei;

(c) performing telomere length analysis to identify fetal nuclei;

(d) collecting fetal nuclei; and

(e) analyzing fetal nuclei.

2. The method of claim 1 , wherein step (d) comprises collecting fetal nuclei by selectively lysing nuclei of unwanted cells relative to fetal nuclei.

3. The method of claim 1 , wherein the microfluidic device comprises a channel having a structure that deterministically directs fetal nucleated cells in a first direction and at least some maternal cells in a second direction based on deterministic lateral displacement.

4. The method of claim 3 , wherein the microfluidic device is a duplex device comprising a channel comprising a first section comprising first and second outer regions, each outer region comprising a structure that deterministically directs particles having a hydrodynamic size above a critical size in a first direction and particles having a hydrodynamic size below the critical size in a second direction, wherein the first and second outer regions are aligned in parallel in the channel.

5. The method of claim 1 , wherein step (e) comprises employing RNA Fluorescence In Situ Hybridization (FISH) for positive or negative selection of fetal nuclei.

6. The method of claim 1 , wherein step (e) comprises employing sequencing for positive or negative selection of fetal nuclei.

7. The method of claim 1 , wherein step (e) comprises analyzing fetal nuclei by micro-dissection.

8. The method of claim 1 , wherein step (e) comprises analyzing fetal nuclei by polymerase chain reaction (PCR) or whole genome amplification (WGA).

9. The method of claim 1 , wherein step (e) comprises analyzing fetal nuclei by analysis of short tandem repeats (STR).

10. The method of claim 1 , wherein step (e) comprises analyzing fetal nuclei by analysis of single nucleotide point mutations (SNP), deletions, or translocations.

11. The method of claim 1 , wherein step (e) comprises analyzing fetal nuclei by detecting chromosomal aneuploidies.

12. The method of claim 11 , wherein chromosomal aneuploidies are detected using comparative genome hybridization.

13. A method of enriching a sample in fetal cells relative to maternal cells, the method comprising:

(a) introducing a maternal blood sample into a microfluidic device capable of enriching fetal nucleated cells relative to maternal cells based on size, shape, deformability, or affinity to produce an enriched sample;

(b) lysing all cells in the enriched sample to release nuclei;

(c) selectively lysing nuclei of unwanted cells and extracting fetal apoptotic DNA from fetal nuclei; and

(d) analyzing the extracted fetal apoptotic DNA.

14. The method of claim 13 , wherein the microfluidic device comprises a channel having a structure that deterministically directs fetal nucleated cells in a first direction and at least some maternal cells in a second direction based on deterministic lateral displacement.

15. The method of claim 14 , wherein the microfluidic device is a duplex device comprising a channel comprising a first section comprising first and second outer regions, each outer region comprising a structure that deterministically directs particles having a hydrodynamic size above a critical size in a first direction and particles having a hydrodynamic size below the critical size in a second direction, wherein the first and second outer regions are aligned in parallel in the channel.

16. The method of claim 13 , wherein step (d) comprises analyzing the extracted fetal apoptotic DNA by polymerase chain reaction (PCR) or whole genome amplification (WGA).

17. The method of claim 13 , wherein step (d) comprises analyzing the extracted fetal apoptotic DNA by analysis of short tandem repeats (STR).

18. The method of claim 13 , wherein step (d) comprises analyzing the extracted fetal apoptotic DNA by analysis of single nucleotide point mutations (SNP), deletions, or translocations.

19. The method of claim 13 , wherein step (d) comprises analyzing the extracted fetal apoptotic DNA by detecting chromosomal aneuploidies.

20. The method of claim 19 , wherein chromosomal aneuploidies are detected using comparative genome hybridization.

Assignments (8)
CERTIFICATE OF CONVERSION FROM A LIMITED LIABILITY COMPANY TO A CORPORATION Recorded Jun 14, 2024
From: GPB SCIENTIFIC, LLC
To: GPB SCIENTIFIC, INC.
Reel/Frame 067737/0606 →
RELEASE OF SECURITY INTEREST Recorded Jun 14, 2024
From: SILICON VALLEY BANK, A DIVISION OF FIRST-CITIZENS BANK & TRUST COMPANY
To: GPB SCIENTIFIC, INC.
Reel/Frame 067732/0146 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2024
From: GPB SCIENTIFIC, INC. (D/B/A CURATE BIOSCIENCES)
To: CURATE (ABC), LLC
Reel/Frame 067737/0738 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2024
From: CURATE (ABC), LLC
To: ZEON CORPORATION
Reel/Frame 067737/0769 →
SECURITY INTEREST Recorded Sep 28, 2023
From: GPB SCIENTIFIC, INC.
To: FIRST-CITIZENS BANK & TRUST COMPANY
Reel/Frame 065082/0354 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2018
From: HUANG, LOTIEN RICHARD; BARBER, THOMAS A.; CARVALHO, BRUCE L.; KAPUR, RAVI; VERNUCCI, PAUL; WANG, ZIHUA
To: VERINATA HEALTH, INC
Reel/Frame 047423/0298 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2018
From: VERINATA HEALTH, INC
To: THE GENERAL HOSPITAL CORPORATION
Reel/Frame 047423/0357 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2018
From: TONER, MEHMET
To: THE GENERAL HOSPITAL CORPORATION; GPB SCIENTIFIC, LLC
Reel/Frame 047431/0339 →
Continuity (7)
Continuation 14930313 · Nov 2, 2015
Division 13232781 · Sep 14, 2011
Continuation 11449149 · Jun 8, 2006
Continuation PCTUS2006012820 · Apr 5, 2006
Continuation 60704067 · Jul 29, 2005
Provisional Application 60668415 · Apr 5, 2005
Related Publication 20190001344A1 · Jan 3, 2019
Cited By (1)
US 12,409,457